Lexaria completes enrollment for diabetes drug study

KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX), a $29.3 million market cap leader in drug delivery platforms, has announced the completion of patient enrollment for its Phase 1b study, GLP-1-H24-4, in Australia. According to InvestingPro data, analysts have set ambitious price targets between $7-8 per share, suggesting significant upside potential if the trial succeeds. The study, which investigates the safety and efficacy of the company’s DehydraTECH technology in oral diabetes medications, has enrolled 24 patients for each of its five arms, exceeding the initial target of 20.

The "last patient in" milestone signals that the treatment phase of the study is expected to conclude in approximately twelve weeks, followed by a comprehensive analysis of the data. Lexaria’s President, John Docherty, expressed satisfaction with the progress, noting that dosing is proceeding as planned and the study is on track for completion.

The trial is evaluating DehydraTECH-enabled formulations of semaglutide, tirzepatide, and cannabidiol (CBD) against a control arm using Rybelsus® tablets, which contain Novo Nordisk’s proprietary SNAC technology. While the company maintains a strong balance sheet with more cash than debt and excellent liquidity (current ratio of 29.6), InvestingPro analysis indicates rapid cash utilization - a critical factor for investors monitoring clinical-stage biotech companies. Subscribers can access 6 additional ProTips and comprehensive financial metrics to better evaluate LEXX’s investment potential. This marks the first time that DehydraTECH-processed pure semaglutide will be directly compared to SNAC-enabled Rybelsus® in a human study over multiple weeks.

In previous studies, Lexaria’s DehydraTECH technology has shown promise in enhancing drug absorption and reducing side effects. The company’s animal study on DehydraTECH-CBD reported significant weight loss and blood glucose reduction, raising expectations for similar outcomes in human trials.

The current study aims to determine the safety of the DehydraTECH-processed drugs over 12 weeks and whether they can outperform the existing Rybelsus® formulation in terms of blood sugar control and weight loss. Additionally, the study will assess if DehydraTECH processing can reduce side effects associated with daily dosing.

Results from the study are projected to be released in the fourth quarter of 2025. Lexaria maintains a robust intellectual property portfolio with 48 granted patents and more pending globally. The company has demonstrated strong revenue growth of 77.6% in the last twelve months, though InvestingPro analysis suggests the stock is currently trading near its Fair Value. With earnings expected in 12 days, investors seeking detailed analysis can access real-time updates and comprehensive financial metrics through InvestingPro’s advanced platform. The company continues to explore the potential of its DehydraTECH platform to improve oral drug delivery across various applications.

This article is based on a press release statement and offers an overview of the ongoing clinical study by Lexaria Bioscience Corp. without promoting the company or its products.

In other recent news, Lexaria Bioscience Corp. has announced the initiation of a human clinical study to test its oral DehydraTECH-liraglutide against the injected form of liraglutide, known as Saxenda®. This follows promising results from a rodent trial showing significant weight and blood sugar reduction. Additionally, Lexaria reported that its oral tirzepatide capsules demonstrated comparable efficacy to the injectable form, Zepbound®, in a recent pharmacokinetic study. The study noted a significant reduction in side effects for the oral capsules, with 47% fewer adverse events compared to the injectable version.

In another development, Lexaria has secured two new patents for its DehydraTECH technology aimed at treating epilepsy, bringing its total to 48 granted patents. The company has also reported successful results from its DehydraTECH studies, highlighting an 18.8% higher semaglutide level in the bloodstream and a 60% reduction in adverse events compared to commercial tablets. Furthermore, H.C. Wainwright has adjusted Lexaria’s stock target from $10 to $7 while maintaining a Buy rating, following positive results from the company’s human pilot study on oral tirzepatide.

Lexaria continues to focus on GLP-1 research, planning further studies and collaborations to enhance drug delivery. The company has also entered a Material Transfer Agreement with an unnamed pharmaceutical entity to evaluate its technology in a pre-clinical setting. These recent developments underscore Lexaria’s ongoing efforts to advance its DehydraTECH technology in the pharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.